1887

oa SA Pharmaceutical Journal - New product focus : drug info

 

Abstract

Entecavir (Baraclude™) is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents over the age of 16 years with evidence of active viral replication and either evidence of persistent elevations in liver enzymes (ALT or AST) or histologically active disease.

Loading

Article metrics loading...

/content/mp_sapj/76/1/EJC82075
2009-01-01
2016-12-09
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error